Roquefort Therapeutics (LON:ROQ) Trading Down 13.8% – What’s Next?

Shares of Roquefort Therapeutics plc (LON:ROQ) fell 13.8% during trading on Tuesday . The stock traded as low as GBX 1.91 ($0.02) and last traded at GBX 2.07 ($0.03). 14,477,742 shares were traded during mid-day trading, an increase of 478% from the average session volume of 2,502,635 shares. The stock had previously closed at GBX 2.40 ($0.03).

Roquefort Therapeutics Price Performance

The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The firm’s fifty day simple moving average is GBX 2.90 and its 200 day simple moving average is GBX 3.62. The firm has a market cap of £2.32 million, a P/E ratio of -1.51 and a beta of 0.05.

Insider Transactions at Roquefort Therapeutics

In related news, insider Stephen Paul West purchased 400,000 shares of the firm’s stock in a transaction on Tuesday, February 4th. The stock was acquired at an average price of GBX 3 ($0.04) per share, with a total value of £12,000 ($15,562.18). Company insiders own 60.40% of the company’s stock.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.